Compare AU
Compare EMMG vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are EMMG and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
EMMG | DRUG | |
---|---|---|
Popularity | Low | Low |
Pearlers invested | 5 | 59 |
Median incremental investment | $1,997.66 | $920.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,080.08 | $1,995.65 |
Average age group | > 35 | 26 - 35 |
Key Summary
EMMG | DRUG | |
---|---|---|
Strategy | EMMG.AX was created on 2019-05-29 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to generate after-fee returns in excess of the MSCI Emerging Markets Index expressed in Australian Dollars over rolling five-year periods. The Fund invests in a portfolio of emerging market shares that is actively managed by Legg Masons wholly-owned equity specialist, Martin Currie | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | BetaShares Martin Currie Em Fund (Managed Fund) (100 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (75.65 %) Communication Services (33.53 %) Health Care (24.23 %) | |
Top 3 countries | China (20.90 %) India (20.69 %) Korea (17.98 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 1 % | 0.57 % |
Key Summary
EMMG | DRUG | |
---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 1 % | 0.57 % |
Price | $6.48 | $8.35 |
Size | $25.535 million | $193.927 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | 0.56 % | 1.89 % |
Market | ASX | ASX |
First listed date | 06/06/2019 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
EMMG | DRUG | |
---|---|---|
Popularity | Low | Low |
Pearlers invested | 5 | 59 |
Median incremental investment | $1,997.66 | $920.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,080.08 | $1,995.65 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
EMMG | DRUG | |
---|---|---|
Pros |
| |
Cons |
|
EMMG | DRUG |
---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |